A randomized clinical study assessing the effects of the antioxidants, resveratrol or SG1002, a hydrogen sulfide prodrug, on idiopathic oligoasthenozoospermia

ObjectiveTo determine whether subjects suffering from oligoasthenozoospermia would benefit from antioxidant treatment with resveratrol, a natural-occurring polyphenol, and hydrogen sulfide.MethodsA randomized controlled clinical trial involving 54 men with Oligoasthenozoospermia. We randomly assigned resveratrol (n=18), SG 1002 (n=18), and placebo (n=18) for 75 days. Sperm analysis was performed after treatment. Statistical analysis was made with chi square test.ResultsWhen compared to the placebo treated group, SG1002 treatment led to an increase in sperm concentration (11.18 × 106 vs. 17.01 × 106, P < 0.05), sperm motility (10.06 × 106 vs. 20.06 × 106, P<0.05) and motile forms recovery (0.33 × 106 vs. 1.62 × 106, P<0.05). Resveratrol treatment did not significantly affect any of the parameters.ConclusionsSG1002 may reverse oligoasthenozoospermia. It seems to be more potent antioxidant than resveratrol. This findings need be supported by further clinical investigation.